Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: fewer (74), minus (30), excluding (249)

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual r
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

MyelomaBortezomib SC DexamethasonePabinostat 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT (21 day) Regimen • Multiple Myeloma – Bortezomi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostat-21day-Ver1.1.pdf

MyelomaBortezomib IV DexamethasonePabinostat 28 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT (28 day) Regimen • Multiple Myeloma – Bortezomi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostat-28-day.pdf

Lifestyle questionnaire

Description: Healthy Mum Healthy Baby Try this quiz to see how healthy your diet is BREAD, RIC
Url: /Media/UHS-website-2019/Docs/Services/Maternity/Lifestyle-questionnaire.doc

Annual report 2021-2022

Description: 2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Pr
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

Brigatinib

Description: Chemotherapy Protocol Lung Cancer Regimen Brigatinib • NSCLC – Brigatinib Indication • Brigatinib is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Brigatinib.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (A
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

UHS AR 22-23-6

Description: 2022/23 Incorporating the quality account University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-22-23-6.pdf

Atezolizumab-Bevacizumab-Carboplatin(AUC6)-Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER ATEZOLIZUMAB-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen  Lu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab-Bevacizumab-CarboplatinAUC6-Paclitaxel.pdf

11 to 20 of 1000

Previous 1 2 3 4 5 … Next